Crossmark

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment

Crossref DOI link: https://doi.org/10.1186/s40425-019-0604-2

Published Online: 2019-05-03

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abu-Sbeih, Hamzah

Tran, Cynthia Nguyen

Ge, Phillip S.

Bhutani, Manoop S.

Alasadi, Mazen

Naing, Aung

Jazaeri, Amir A.

Wang, Yinghong http://orcid.org/0000-0002-5148-6130
License Information

Text and Data Mining valid from 2019-05-03
More Information

Article History

Received: 22 February 2019

Accepted: 23 April 2019

First Online: 3 May 2019

Ethics approval and consent to participate

: The ethics approval of this study was granted by the Institutional Review Board committee at The University of Texas MD Anderson Cancer Center (PA18–0472). Consent was waived for this study.

: This study was granted a waiver for consent.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.